Investor Relations

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of  patients with elevated LDL-C.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Aug 26, 2016
Last Price Change Open Day High 52-Week High
0.13  up   (1.238%) 10.58 10.75 55.23
Volume Previous Close Day Low 52-Week Low
251,462 10.50 10.31 9.58

View all »   RSSRecent Releases

Aug 4, 2016
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results

Jun 28, 2016
Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid